Analyst Reco. Galapagos NV

Equities

GLPG

BE0003818359

Market Closed - Euronext Amsterdam Other stock markets 11:35:19 2024-06-06 am EDT			After market 01:43:00 pm
25.02 ^EUR	-0.48%		24.95	-0.28%

May. 31	Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	MT
May. 31	Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says	Mar. 28	MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41	Mar. 28	MT
JPMorgan Cuts Galapagos Price Target to $37 From $45, Maintains Neutral Rating	Dec. 05	MT
Morgan Stanley Adjusts Galapagos' Price Target to $40 From $42, Keeps Equalweight Rating	23-08-07	MT
RBC Cuts Price Target on Galapagos to $38 From $41, Keeps Sector Perform Rating	23-08-07	MT
JPMorgan Lowers Price Target on Galapagos to $45 From $52, Maintains Neutral Rating	23-05-31	MT
Berenberg USA Conference	23-05-22	FA
Morgan Stanley Adjusts Price Target on Galapagos to $42 From $44, Keeps Equalweight Rating	23-05-09	MT
Raymond James Upgrades Galapagos to Outperform From Market Perform, Price Target is $69	23-05-08	MT
RBC Cuts Price Target on Galapagos to $41 From $43 Amid 'Slowed Adoption' of Jyseleca, Maintains Sector Perform Rating	23-05-08	MT
Morgan Stanley Adjusts Price Target on Galapagos to $44 From $57, Maintains Equal-Weight Rating	23-02-27	MT
RBC Cuts Price Target on Galapagos to $43 From $53, Maintains Sector Perform Rating	23-02-27	MT
Jefferies Upgrades Galapagos to Hold From Underperform, Adjusts Price Target to $47.20 From $49	23-01-23	MT
RBC Lowers Price Target on Galapagos to $53 From $55, Keeps Sector Perform Rating	22-11-07	MT
Morgan Stanley Adjusts Galapagos' Price Target to $63 from $61, Keeps Equalweight Rating	22-10-13	MT
Morgan Stanley Downgrades Galapagos to Equalweight From Overweight, Cuts Price Target to $61 From $80	22-09-09	MT
Morgan Stanley Raises Galapagos NV's Price Target to $80 From $79, Maintains Overweight Rating	22-08-15	MT
RBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating	22-08-08	MT
Morgan Stanley Adjusts Galapagos' Price Target to $79 from $80, Keeps Overweight Rating	22-07-15	MT
RBC Raises Price Target on Galapagos to $62 From $60, Maintains Sector Perform Rating	22-05-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Galapagos NV

Equities

GLPG

BE0003818359

Analyst Reco.

Filters